Molecular Structure of Furacilin (CAS NO.59-87-0):

IUPAC Name: [(E)-(5-nitrofuran-2-yl)methylideneamino]urea
Molecular Formula: C₆H₆N₄O₄
Formula Weight: 198.14
Melting point: 242-244 ^°C(lit.)
Flash Point: 2 °C
H bond acceptors: 8
H bond donors: 3
Freely Rotating Bonds: 3
Polar Surface Area: 94.87 Å²
Index of Refraction: 1.674
Molar Refractivity: 43.56 cm³
Molar Volume: 116 cm³
Surface Tension: 81 dyne/cm
Density: 1.7 g/cm³
Storage temp: 2-8^°C
Water Solubility: <0.1 g/100 mL at 19 ^oC
Sensitive: Light Sensitive
EINECS: 200-443-1
Product Categories: Furan&Benzofuran; NA - NIAntibiotics; Alphabetic; Chemical Structure; N; Others

FURFURAL by nitration, esterification, hydrolysis, System 5-nitro - FURFURAL, and with condensation hydrochloride derived amino Nitrofurazone.

IARC Cancer Review: Group 3 IMEMDT    IARC Monographs on the Evaluation of Carcinogenic Risk of chemicals to Man . 50 ,1990,p. 195.(World Health Organization, Internation Agency for Research on Cancer,Lyon, France.: ) (Single copies can be ordered from WHO Publications Centre U.S.A., 49 Sheridan Avenue, Albany, NY 12210) ; Animal Limited Evidence IMEMDT    IARC Monographs on the Evaluation of Carcinogenic Risk of chemicals to Man . 50 ,1990,p. 195.(World Health Organization, Internation Agency for Research on Cancer,Lyon, France.: ) (Single copies can be ordered from WHO Publications Centre U.S.A., 49 Sheridan Avenue, Albany, NY 12210) ; Animal Inadequate Evidence IMEMDT    IARC Monographs on the Evaluation of Carcinogenic Risk of chemicals to Man . 7 ,1974,p. 171.(World Health Organization, Internation Agency for Research on Cancer,Lyon, France.: ) (Single copies can be ordered from WHO Publications Centre U.S.A., 49 Sheridan Avenue, Albany, NY 12210) ; Human No Adequate Data IMEMDT    IARC Monographs on the Evaluation of Carcinogenic Risk of chemicals to Man . 7 ,1974,p. 171.(World Health Organization, Internation Agency for Research on Cancer,Lyon, France.: ) (Single copies can be ordered from WHO Publications Centre U.S.A., 49 Sheridan Avenue, Albany, NY 12210) ; Human Inadequate Evidence IMEMDT    IARC Monographs on the Evaluation of Carcinogenic Risk of chemicals to Man . 50 ,1990,p. 195.(World Health Organization, Internation Agency for Research on Cancer,Lyon, France.: ) (Single copies can be ordered from WHO Publications Centre U.S.A., 49 Sheridan Avenue, Albany, NY 12210) . Reported in NTP Carcinogenesis Studies (feed); Clear Evidence: rat, mouse NTPTR*    National Toxicology Program Technical Report Series. (Research Triangle Park, NC 27709) No. NTP-TR-337 ,1988. . Reported in EPA TSCA Inventory. EPA Genetic Toxicology Program.

Hazard Codes: XnF
Risk Statements: 22-36-20/21/22-11 
R22:Harmful if swallowed. 
R36:Irritating to eyes. 
R20/21/22:Harmful by inhalation, in contact with skin and if swallowed. 
R11:Highly flammable.
Safety Statements: 36-36/37-26 
S36:Wear suitable protective clothing. 
S36/37:Wear suitable protective clothing and gloves. 
S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
RIDADR: 3249
WGK Germany: 3
RTECS: LT7700000
F: 8
HazardClass: 6.1(b)
PackingGroup: III
Poison by ingestion and intraperitoneal routes. Moderately toxic by subcutaneous route. Questionable carcinogen with experimental carcinogenic, neoplastigenic, tumorigenic, and teratogenic data. Experimental reproductive effects. A human sensitizer. Human mutation data reported. When heated to decomposition it emits toxic fumes of NO_x.

  Furacilin , with CAS number of 59-87-0, can be called Nitrofuraldehyde semicarbazone ; Nitrofuran ; Nitrofurazone ; Nitrofuran(bactericide) ; Veterinarynitrofurazone ; Mammex ; 5-Nitro-2-furfuraldehyde semicarbazone ; 5-Nitro-2-furfuralsemicarbazone ; 5-Nitro-2-furaldehyde semicarbazone ; 2-Furancarboxaldehyde, 5-nitro-,semicarbazone ; 2-Furaldehyde,5-nitro-, semicarbazone (6CI,7CI,8CI) . Furacilin (CAS NO.59-87-0) is used as an antibiotic most commonly in the form of ointments. Its use in medicine has become less frequent as safer and more effective products have become available.